Press-release for stocks related to program for eli lilly and company

tags : Program entities : Eli lilly and company

save search

Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
Published: 2024-03-12 (Crawled : 12:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M

Health Technology

| -8.35% | O: -0.21% H: 0.11% C: -1.06%
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| -1.1% | O: 0.9% H: 2.03% C: 1.89%
VERU | $1.305 -8.1% -8.81% 2.6M

Health Technology

| 99.09% | O: -0.53% H: 2.22% C: -3.59%
ALT | $6.91 0.29% 0.29% 3.6M

Commercial Services

| -29.99% | O: 0.3% H: 11.41% C: 9.8%
medical program

Veru Inc.’s Oncology Drug Research Program Partner, The University of Tennessee Health Science Center, Awarded Two New Federal Grants
Published: 2023-06-21 (Crawled : 12:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 60.71% | O: 0.56% H: 0.18% C: -0.33%
VERU | $1.305 -8.1% -8.81% 2.6M

Health Technology

| 7.38% | O: 0.82% H: 0.0% C: -1.63%
drug health research program grants

Verve Establishes Global Collaboration with Lilly to Advance Verve’s In Vivo Gene Editing Program Targeting Lp(a) for the Treatment of Atherosclerotic Cardiovascular Disease
Published: 2023-06-15 (Crawled : 11:00) - globenewswire.com
VERV | News | $6.64 -0.3% -0.3% 1.1M

Professional, Scientific, and T...

| -61.17% | O: 2.4% H: 14.05% C: 13.31%
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 62.22% | O: 0.06% H: 1.91% C: 1.32%
disease treatment global collaboration program cardiovascular

Lilly Discloses First-in-Class, Interim Phase 2 Data in Pediatric Patients and New Analysis from Phase 3 Program in Adult Patients for Mirikizumab in Ulcerative Colitis
Published: 2023-05-09 (Crawled : 12:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 67.85% | O: -0.22% H: 0.89% C: -0.79%
program

Veru Announces Preclinical Results from Expanded Sabizabulin Program into Influenza-Induced Severe Acute Respiratory Distress Syndrome and Provides Update on COVID-19 Program
Published: 2023-04-04 (Crawled : 14:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 107.08% | O: 0.38% H: 1.97% C: 0.72%
VERU | $1.305 -8.1% -8.81% 2.6M

Health Technology

| 14.91% | O: 7.89% H: 1.63% C: -9.76%
covid-19 sabizabulin respiratory update preclinical program results

IgGenix Announces First Close of $40M Series B Financing to Accelerate Lead Antibody Program in Peanut Allergy
Published: 2023-02-06 (Crawled : 15:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 114.2% | O: 0.86% H: 0.42% C: -1.26%
ARE A | $115.69 -0.7% 0.0% 940K

Finance

| -31.05% | O: -1.29% H: 1.54% C: 0.98%
antibody peanut program

Jury Orders Eli Lilly to Pay $61 Million in Damages for Defrauding Federal Medicaid Program
Published: 2022-08-04 (Crawled : 17:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 131.43% | O: -1.16% H: 0.02% C: -1.42%
program

ALX Oncology Announces Evorpacept Clinical Program Updates
Published: 2022-06-03 (Crawled : 12:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 134.29% | O: -2.25% H: 0.0% C: 0.0%
ALXO M | $15.6 -0.89% -0.9% 480K

Commercial Services

| 111.67% | O: 1.49% H: 3.07% C: 1.6%
program

NeoGenomics Inc. Announces Partnership with Lilly for Lung Cancer Sponsored Testing Program Utilizing the NeoTYPE(R) DNA and RNA Assay
Published: 2022-04-25 (Crawled : 12:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 151.99% | O: -3.29% H: 2.58% C: 2.31%
NEO | $13.54 -1.67% -1.7% 770K

Health Services

| 19.52% | O: -2.83% H: 2.64% C: 2.27%
partnership program cancer test

Kyttaro Announces Worldwide Exclusive Licensing Agreement With Lilly for Antibody Therapeutic Program
Published: 2022-04-11 (Crawled : 13:20) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 133.02% | O: 0.45% H: 0.21% C: -1.32%
antibody program license

Arkuda Therapeutics Raises $64 Million Series B Financing to Advance Pipeline of Programs Targeting Lysosomal Biology to Treat Neurodegenerative Diseases
Published: 2022-02-10 (Crawled : 12:30) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 200.89% | O: -0.69% H: 0.0% C: 0.0%
program therapeutics disease neurodegenerative

Foundation Medicine Announces Global Collaboration With Lilly to Develop FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for RETEVMO® and Loxo Oncology at Lilly’s Pipeline Programs
Published: 2022-02-09 (Crawled : 12:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 200.25% | O: -0.21% H: 0.0% C: 0.0%
foundationone diagnostic program diagnostics one collaboration

Lilly’s Olumiant Portfolio Takes a Pair of Hits as Lupus Program Discontinued
Published: 2022-01-28 (Crawled : 19:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 206.82% | O: 0.33% H: 3.25% C: 3.2%
olumiant program air lupus

Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis
Published: 2022-01-28 (Crawled : 14:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 206.82% | O: 0.33% H: 3.25% C: 3.2%
INCY | $52.3 -0.98% -0.99% 2.2M

Health Technology

| -26.88% | O: -0.2% H: 3.93% C: 3.89%
olumiant fda atopic dermatitis program dermatitis baricitinib phase 3 lupus

Rigel Pharmaceuticals Provides Update on COVID-19 Program
Published: 2021-08-13 (Crawled : 12:15) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 175.67% | O: 0.2% H: 0.0% C: 0.0%
RIGL | $1.07 1.91% 1.87% 810K

Health Technology

| -73.85% | O: -16.22% H: 0.0% C: 0.0%
covid covid-19 program

HHS Withdraws Advisory Opinion on 340B Drug Discount Program
Published: 2021-06-21 (Crawled : 19:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M

Health Technology